Floatz logo

Aztreonam Lysine

Pseudomonas Aeruginosa Infectious Disease

Gilead SciencesUNKNOWNPhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Pseudomonas Aeruginosa Infectious Disease cohort.

Asset / SponsorPhaseRating
Ap-Pa02
Armata Pharmaceuticals, Inc.
Phase 2BB
Piperacillin
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB
Ceftolozane
Sunshine Coast Hospital and Health Service
Phase 4BB
Tazobactam
Sunshine Coast Hospital and Health Service
Phase 4BB
Pseudomonas Aeruginosa-Specific Bacteriophage Mixture, Live Consisting Of 3 Bacteriophages (Ihma-2121771-1, Ihma-2121771-2, Ihma-2121908-1)
BiomX Ltd
Phase 2BB

View all 12 →

Same molecule, other indications

Aztreonam Lysine is also rated in:

cystic fibrosisDormant
BB
Indicative · Phase 3
68 / 100
View asset →
bronchiectasisDormant
BB
Indicative · Phase 3
66 / 100
View asset →
pneumoniaDormant
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →